Publicaciones en colaboración con investigadores/as de Fundación Hospital Alcorcón (150)

2023

  1. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness

    Journal of Parkinson's disease, Vol. 13, Núm. 2, pp. 219-231

  3. ClinPrior: an algorithm for diagnosis and novel gene discovery by network-based prioritization

    Genome medicine, Vol. 15, Núm. 1, pp. 68

  4. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  5. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2

  6. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  7. Falls Predict Acute Hospitalization in Parkinson's Disease

    Journal of Parkinson's disease, Vol. 13, Núm. 1, pp. 105-124

  8. First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

    Journal of Investigational Allergology and Clinical Immunology

  9. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  10. Impact of hypertension diagnosis on morbidity and mortality: a retrospective cohort study in primary care

    BMC Primary Care, Vol. 24, Núm. 1

  11. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  12. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159